At the time of writing, Inovio Pharmaceuticals Inc [INO] stock is trading at $9.87, up 1.96%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The INO shares have gain 16.67% over the last week, with a monthly amount glided 101.43%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights. In a post published today on Yahoo Finance, Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP).
From an analyst’s perspective:
Inovio Pharmaceuticals Inc [NASDAQ: INO] stock has seen the most recent analyst activity on January 25, 2024, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $4 for it. Previously, Maxim Group downgraded its rating to Hold on November 09, 2022. On November 01, 2022, downgrade downgraded it’s rating to Underperform but maintained its price target of $2 on the stock. Oppenheimer downgraded its rating to a Perform. BofA Securities upgraded its rating to Neutral for this stock on January 21, 2022, and upped its price target to $10.
For the past year, the stock price of Inovio Pharmaceuticals Inc fluctuated between $3.89 and $15.73. Inovio Pharmaceuticals Inc [NASDAQ: INO] shares were valued at $9.87 at the most recent close of the market.
Analyzing the INO fundamentals
According to Inovio Pharmaceuticals Inc [NASDAQ:INO], the company’s sales were 0.85M for trailing twelve months, which represents an -95.76% plunge. Gross Profit Margin for this corporation currently stands at -38.46% with Operating Profit Margin at -201.98%, Pretax Profit Margin comes in at -192.71%, and Net Profit Margin reading is 3310.9%. To continue investigating profitability, this company’s Return on Assets is posted at 14.64, Equity is 15.51 and Total Capital is -1.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.59 points at the first support level, and at 9.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.23, and for the 2nd resistance point, it is at 10.59.
Inovio Pharmaceuticals Inc [INO] reported earnings per share of -$1.56 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.52/share, meaning a difference of -$0.04 and a surprise factor of -2.60%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$1.56 per share as compared to estimates of -$1.74 per share, a difference of $0.18 representing a surprise of 10.30%.
Ratios To Look Out For
It is important to note that Inovio Pharmaceuticals Inc [NASDAQ:INO] has a current ratio of 4.00. Also, the Quick Ratio is 4.00, while the Cash Ratio stands at 0.43. Considering the valuation of this stock, the price to sales ratio is 264.17, the price to book ratio is 1.61.
Transactions by insiders
Recent insider trading involved Zoth Lota S., Director, that happened on Jun 05 ’23 when 5700.0 shares were sold. Director, Weiner David B. completed a deal on Mar 13 ’23 to sell 5833.0 shares.
